The repletion ofiron stores after treatment was studied in 38 patients with uncomplicated iron-deficiency anaemia. The serum ferritin concentration rose significantly when oral treatment was continued for two months after the attainment of a normal haemoglobin concentration. Patients treated with a total-dose infusion of iron dextran had the highest final serum levels, which were significantly greater than in patients given Ferro-Gradumet. Oral ferrous sulphate was almost as effective as parenteral iron in producing iron stores.
During the past 12 months in our unit four infants have died antenatally. Each mother had reported absent fetal movements for at least 12 hours before the fetal heart became inaudible. During this time each patient underwent external cardiotocography using Doppler ultrasound without fetal response. Other patients who recorded low daily fetal movement counts (below 11/24 h) and in whom the fetal outcome was satisfactory showed an increase in fetal activity during the 24 hours after a one-hour exposure to Doppler ultrasound; however, the reverse was not always true. Though we do not know why the fetus responds to Doppler ultrasound, it is a procedure without known risk,' and we think that with further development the study of this response might provide further information about the fetus.
Introduction
In the management of patients with iron-deficiency anaemia it is generally recommended that oral treatment should be Welsh National School of Medicine, University Hospital of Wales, Cardiff CF4 4XN D. P. BENTLEY, M.B., M.R.C.P., Lecturer in Haematology A. JACOBS, M.D., F.R.C.PATH., Professor of Haematology continued for several weeks after the peripheral blood has returned to normal so that iron stores are adequately replenished." 2 The validity of this concept remains unproved as the repeated measurement of body iron stores during treatment has not previously been feasible. Measurement of the serum ferritin concentration, however, provides a simple and accurate means for assessing iron stores,3 and we have used this in patients being treated for simple iron-deficiency anaemia as a guide to the rate at which storage iron accumulates.
Patients and Methods
All the patients studied had iron-deficiency anaemia with a haemoglobin concentration of less than 10 g/dl, a mean corpuscualr volume (M.C.V.) of less than 75 fl, and a mean corpuscular haemoglobin concentration of less than 25 pg. The peripheral blood films all showed hypochromic, microcytic red cells. In all cases the serum iron concentration was less than 7 ,umol/l (39 tg/100 ml), the total iron binding capacity greater than 70 ,umol/l (390 [tg100 ml), and the transferrin saturation less than 10%. The patients were allocated at random to four treatment groups. Group 1 received a total-dose infusion of iron dextran (Imferon) according to the manufacturer's instructions; group 2 ferrous sulphate tablets (200 mg three times daily); group 3 Ferro-Gradumet one tablet daily; and group 4 Ferrograd C one tablet daily. Ferro-Gradumet is a controlled-release preparation containing 525 mg ferrous sulphate in each tablet, while Ferrograd C also contains 500 mg ascorbic acid in each tablet. All patients except those in group 1 were treated until two months after Total-dose infusion 8-8±0-8 64-8±4-5 4-15 ±1-34 4-3±0-6 13-5±0-2 91-3±1-8 2040±1-25 33-5±1-6 (7 months after treatment) Conversion: SI to Traditional Units: Iron: 1 ,umol/l 5-6 ,ug/100 ml.
they had first attained a normal haemoglobin concentration (over 12-5 g/dl in women and 13-5 g/dl in men).
All the men and postmenopausal women were investigated for gastrointestinal blood loss by faecal examination for occult blood, sigmoidoscopy, proctoscopy, and barium meal and enema examinations. Menstruating women were not extensively investigated unless their iron deficiency had arisen possibly from other than excessive menstrual loss. Patients with a gastrointestinal lesion or systemic disorder likely to affect the therapeutic response were excluded. All who completed the study showed a satisfactory response to treatment and only one relapsed within the next 12 months.
Haemoglobin Patients with iron-deficiency anaemia and depleted iron stores have serum ferritin concentrations under 12 ,ug/1,3 6 and this was found in the present study (table II) . In 18 of the 26 patients on oral treatment the serum ferritin concentration was over 20 [±g/l when the haemoglobin concentration had reached normal levels. These patients were equally distributed throughout all the groups. The mean serum ferritin concentration at that stage was higher in patients taking ferrous sulphate tablets than in those taking the other oral preparations but this was not statistically significant. In the last two months of treatment, during which iron was given after correction of the anaemia the serum ferritin concentrations rose significantly in patients taking ferrous sulphate (t=4-27; P<0.01) and Ferrograd C (t = 2-6; P <0-05). This was not observed in those on Ferro-Gradumet. The mean serum ferritin concentrations for all patients on oral treatment were 30 5,ug/l after correction of the anaemia and 60-1 ,ug/l (t=4-44; P<0-001) after two months of further treatment. At the end of the full course only two patients had serum ferritin concentrations under 20 [Lgll.
In the patients taking oral preparations there was no significant difference between the mean serum ferritin concentrations at the end of treatment. Those treated by total-dose infusion of iron dextran, however, had a significantly higher serum ferritin concentration seven months after treatment than that found at the end of treatment in those who had received Ferro-Gradumet (t=2-5; P<0-01) or Ferrograd C (t=2-4; P<0-02) but not in those who had received ferrous sulphate (t= 1.55; P >0-05).
In some patients the serum ferritin concentration was measured on several occasions during treatment, and in these an initial slight rise was followed by a greater rise when the haemoglobin depletion had been corrected ( fig.) . The final serum ferritin concentration was maintained after treatment. 
Discussion
Patients with iron-deficiency anaemia respond to oral treatment as rapidly and completely as they do to parenteral treatment.7 Little is known, however, of the efficacy of oral treatment in restoring iron stores. Beutler et al.' showed the absence of stainable marrow iron in patients treated for up to four weeks with oral iron, whereas patients treated for longer periods developed visible iron deposits, and thus continued treatment after restoration of the haemoglobin concentration to normal has been recommended. The lack of sensitivity of this method in assessing iron stores compared with the measurement of serum ferritin concentration has been shown. 9 Our results show that a large proportion of patients acculumate iron stores during the period of i,ncreasing haemoglobin concentration. Iron, however, stimulates ferritin synthesis in vivo.'0 Siimes et al."l found a rapid rise in the serum ferritin concentration in the first week of treatment with oral ferrous sulphate in patients with iron-deficiency anaemia, suggesting that an inappropriately high serum ferritin concentration may be found in those taking iron. We found an initial slight rise in the serum ferritin con-centration at the beginning of treatment and a further rise once the haemoglobin depletion had been corrected. The serum ferritin concentration was maintained after treatment had been discontinued and the values found in all groups corresponded to those in normal people. Our data support the view that oral treatment should be continued for two months after the haemoglobin concentration has reached normal levels to replete iron stores. More-prolonged administration of iron is not indicated. Though high serum ferritin concentrations were found in some patients treated by total-dose infusion of iron dextran the results with oral ferrous sulphate were similar, suggesting that parenteral therapy has no special advantage.
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Introduction
Peripheral neuropathy is a well-recognized complication of rheumatoid arthritis, 13 Investigations did not show any underlying cause for his neuropathy; in particular, we found no evidence of a neoplasm. The progress of the illness was unlike a Guillain-Barre syndrome, and the fact that he was negative for rheumatoid factor was unusual for a rheumatoid neuropathy of this severity. The possibility of a druginduced peripheral neuropathy was considered. Three cases of neuropathy in association with the use of indomethacin had previously been reported to the Committee on Safety of Medicines, so indomethacin was discontinued on 17 July 1973 and replaced by phenylbutazone suppositories. Benorylate had been discontinued on admission and he continued on frusemide for his ankle oedema. Before stopping indomethacin he had continued to deteriorate, but by 21 July he began to show some improvement in his walking. The paraesthesiae
